The Holistic Study

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

December 31, 2029

Conditions
Thrombocytopenia Purpura
Interventions
DRUG

Avatrombopag

Daily tablets

DRUG

Rituximab (Arm B)

I.V.

All Listed Sponsors
collaborator

Oslo University Hospital

OTHER

collaborator

University Hospital, Akershus

OTHER

collaborator

Sykehuset i Vestfold HF

OTHER

collaborator

St. Olavs Hospital

OTHER

collaborator

Helse Stavanger HF

OTHER_GOV

collaborator

Sorlandet Hospital HF

OTHER_GOV

collaborator

University Hospital of North Norway

OTHER

collaborator

Haukeland University Hospital

OTHER

collaborator

Helse Nord-Trøndelag HF

OTHER

collaborator

Helse Fonna

OTHER

collaborator

Nordlandssykehuset HF

OTHER

lead

Ostfold Hospital Trust

OTHER

NCT07051915 - The Holistic Study | Biotech Hunter | Biotech Hunter